Novo Nordisk ups guidance after Q1 results beat expectations By Reuters

0
10

© Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo

COPENHAGEN (Reuters) – Denmark’s Novo Nordisk (NYSE:), the world’s biggest manufacturer of diabetes drugs, raised its financial forecast in local currencies on Wednesday after reporting first quarter sales and earnings above expectations.

“We are very encouraged with the sales growth in the first three months of 2021,” Chief Executive Lars Fruergaard Jorgensen said.

“Sales growth was driven by all therapy areas and across geographical areas.”

Novo Nordisk now expects sales growth in local currencies for 2021 at between 6% and 10%, up from a previous 5% to 9% and operating profit growth in local currencies in the range of 5% to 9%, up from a previous estimate of 4% to 8%.

In Danish crowns, Novo still forecasts sales growth to come in 4% lower than in local currencies and operating profit growth 6% lower than in local currencies.

Reported net sales came in flat in the first quarter at 33.8 billion Danish crowns ($5.46 billion), above a forecast of 32.5 billion in a Refinitiv poll.

Sales were driven by a 13% rise in sales of its GLP-1 products, which imitate an intestinal hormone that stimulates production of insulin, offsetting a 7% overall decline in insulin sales.

Novo reported quarterly operating profit of 14.98 billion Danish crowns, above an average of 14.6 billion expected by analysts.

The company said its ongoing share buyback programme will be expanded to 18 billion Danish crowns.

($1 = 6.1881 Danish crowns)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.